Manages symptom complex of tension (or muscle contraction) headache. Sold as Fioricet W/ Codeine. Every FDA application for this active ingredient: 1 branded and 7 generic.
As of Nov 16, 2026, FDA lists 8 applications for Acetaminophen; Butalbital; Caffeine; Codeine Phosphate (sold as Fioricet W/ Codeine), first approved Jul 30, 1992, with 0 new uses approved and 0 published complete response letters.
| Jul 30, 1992 | Fioricet W/ CodeineNDA 20232 ยท New formulation or manufacturer | Actavis Labs Ut Inc | 29 | Marketed |
| Mar 23, 2001 | Butalbital, Acetaminophen, Caffeine And Codeine PhosphateANDA 75618 | Hikma Intl Pharms | 10 | Discontinued |
| Aug 22, 2001 | Phrenilin With Caffeine And CodeineANDA 74911 | Valeant | 4 | Discontinued |
| Apr 22, 2002 | Butalbital, Acetaminophen, Caffeine And Codeine PhosphateANDA 75929 | Pharmobedient | 9 | Discontinued |
| Aug 21, 2003 | Butalbital, Acetaminophen, Caffeine And Codeine Phosphate, Butalbital; Acetaminophen; Caffeine; CodeineANDA 76528 | Able | 0 | Marketed |
| Jun 10, 2004 | Butalbital, Acetaminophen, Caffeine And Codeine PhosphateANDA 76560 | Lgm Pharma | 7 | Marketed |
| Jul 8, 2020 | Butalbital, Acetaminophen, Caffeine And Codeine PhosphateANDA 204649 | Quagen | 2 | Discontinued |
| Jan 26, 2022 | Butalbital, Acetaminophen, Caffeine And Codeine PhosphateANDA 215138 | Hikma | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA